Objective To systematically review the effectiveness and safety of statins for chronic obstructive pulmonary diseases (COPD) combining with pulmonary hypertension (PH).Methods The electronic searches in databases of PubMed,EMbase,the Cochrane Library,Web of Science,CBM,CNKI,VIP and Wanfang Data were conducted from the date of their establishment to January 2016 and the references of the include studies were also retrieved for collecting randomized controlled trials (RCTs) or quasi-RCTs on statins treating COPD combining with PH.Two researchers independenlty screened the literature according to the inclusion and exclusion criteria,extracted the data,assessed the quality of the included studies by adopting the Cochrane collaboration' s tool for assessing risk of bias,and performed Meta-analysis by using RevMan 5.3 software.Results A total of 24 studies involving 1 587 cases were included.The results of Meta-analysis showed that:compared with the control group,simvastatin significantly improved FEV1 [MD =0.23,95％ CI:0.16-0.31,P ＜ 0.000 01],FEV1 ％ [MD =6.73,95％ CI:1.34-12.12,P =0.01],FVC [MD =0.39,95％ CI:0.34-0.45,P ＜ 0.000 01],6 minutes walk distance (6MWD)· [MD=59.09,95％CI:54.24-63.93,P ＜0.000 01] and decreased mPAP [MD=6.73,95％ CI:1.34-12.12,P =0.01],SPAP [MD =-4.53,95 ％ CI =-8.87--0.19,P =0.04].Atorvastatin significantly improved FEV1 [MD =6.22,95 ％ CI:2.51-9.93,P =0.001] and 6 MWD [MD =24.10,95 ％ CI:12.98-35.23,P ＜ 0.000 1] and decreased sPAP [MD =-6.44,95％CI:-7.95--4.93,P＜0.00001] andmPAP [MD=-3.51,95％CI:-5.81--1.22,P=0.003].But no significant difference was found in the improvement of FEV1,FVC or FEV1/FVC.Fluvastatin significantly decreased sPAP [MD=-5.89,95％ CI:-6.99--4.79,P ＜0.000 01].There was a significant decrease in the Borg dyspnoea score in statins group [MD =-3.37,95％ CI:-4.61--2.14,P ＜ 0.000 01] as compared with the controls.In addition,the incidence of adverse drug reactions (ADRs) was similar between statins and the control group.Conclusion Current evidence suggests that statins may decrease pulmonary hypertension in patients with COPD combining with PH.However,high-quality clinical trials with large sample size are needed to verify whether the improvement of pulmonary function,6MWD and Borg dyspnoea score are the class effect or the incidence of ADRs is disparate among different statins.

OBJECTIVETo study the compatibility of composite herbal medicines of the Zishen pill.

METHOD50% ethanol extract test solution of the different combinations of composite herbal medicines of the Zishen pill were prepared. Pharmacologic experiments, such as anti-inflammatory, carbon particle clearance of RES were carried out with the solutions, and the corresponding pharmacological data were obtained. Variance analysis, canonical correlation and stepwise regression analysis were applied to interrelate the amount of each drug and the pharmacological data.

RESULTThe results confirmed that Huangbo and Zhimu were the basis, while Rougui was the corrigent, which was conformed to the theory of TCM.

CONCLUSIONThis study provides a significant try for studying the compatibility of composite herbal medicines.

Anemarrhena ; chemistry ; Animals ; Anti-Inflammatory Agents, Non-Steroidal ; pharmacology ; Carbon ; pharmacokinetics ; Cinnamomum ; chemistry ; Drug Combinations ; Drug Interactions ; Drugs, Chinese Herbal ; isolation & purification ; pharmacology ; Ear ; pathology ; Ear Diseases ; pathology ; Edema ; pathology ; Male ; Metabolic Clearance Rate ; drug effects ; Mice ; Phellodendron ; chemistry ; Plants, Medicinal ; chemistry

Rapid screening and characterization of bioactive compounds from traditional Chinese medicines ( TCM) is one of the highlighted re-search challenges in the field of drug development.Target molecule affin-ity coupled with mass spectrometry ( MS) has become a new method for the screening of bioactive compounds from complex mixture, the recent development of which since 2005 will be reviewed.According to the prin-ciple of affinity screening, the methods could be classified into pre -column affinity screening including ultrafiltration -MS, size -exclusion chromatography-MS, turbulent-flow chromatography-MS, restricted-access material-MS and immobilized target-MS and post-column af-finity screening (HPLC-continuous-flow bioassay-MS).Each meth-od with its typical applications would be introduced, providing technique references for the screening of bioactive compounds from complex mixture such as TCM.

Objective To develop a HPLC method for simultaneous de-termination of six coumarins in Radix Glehniae from different sources. Methods The samples were analyzed by HPLC after pressurized liquid extraction ( PLE ) .The chromatographic conditions were as following:The column was Kinetex core-shell-C18 column (50 mm ×4.6 mm, 2.6 μm) , the mobile phase consisted of acetonitrile-water using gradi-ent elution, the flow rate was 0.4 mL? min-1 and the column tempera-ture was 30℃.The detection wavelength was set at 310 nm and the sam-ple injection volume was 20 μL.The method was validated by investiga-ting its specificity, linearities and limit of detection, precision, extraction recovery, stability and repeatability.Results Six components were de-termined by HPLC, including psoralen, xanthotoxin, bergapten, impera-torin, cnidilin and isoimperatorin. The linearities of them were good ( r≥0.999 2 ) in the concentration ranges of 0.50 -10.00 , 1.00-20.00, 0.32-6.40, 0.25 -5.00, 0.05 -1.00, 0.17 -3.50μg? mL-1 , respectively.The coumarins showed the overall recoveries ranging from 91.7%-107.6%.The contents of six compounds of Radix Glehniae from different areas had an obvious difference.Conclusion Six coumarins in Radix Glehniae were analyzed by PLE and HPLC. The method has good specificity, reproducibility and high sensitivity, which can be applied for the quality control of Radix Glehniae.

Currently available monotherapies of oral nucleoside/nucleotide analogs or interferon are unable to achieve a sustained and effective response in most of patients with chronic hepatitis B (CHB). The objective of the present study was to compare the efficacy and safety of pegylated interferon (Peg-IFN) alpha-2b plus adefovir dipivoxil combination therapy versus Peg-IFN alpha-2b alone. Sixty-one HBeAg-positive chronic hepatitis B patients were randomized to receive Peg-IFN alpha-2b alone (1.5 μg/kg once weekly) or Peg-IFN alpha-2b plus adefovir (10 mg daily) for up to 52 weeks. Efficacy and safety analyses were performed on all participants who received at least one dose of study medication. The rate of HBeAg seroconversion and undetectable HBV-DNA were evaluated after 52 weeks of therapy. At the end of treatment, 11 of 30 (36.7%) patients receiving combination therapy achieved HBeAg seroconversion versus 8 of 31 (25.8%) in the monotherapy group (P=0.36). In contrast, the percentage of patients with undetectable serum HBV DNA was significantly higher in the combination group than in the monotherapy group (76.7% vs. 29.0%, P<0.001). Thyroid dysfunction was more frequent in the combination group than in the monotherapy group (P<0.05). In HBeAg-positive CHB, combination of Peg-IFN alpha-2b and adefovir for 52 weeks resulted, at the end of treatment, in a higher virological response but without significant impact on the rate of HBeAg seroconversion and possibly an adverse effect on thyroid function.

Myeloid differentiation factor MyD88 is a critical adaptor molecule that integrates and transduces intracellular signals in inducing the differentiation of dendritic cells (DCs).The domain regions within MyD88 was searched,it could potentially affect the function of dendritic cells and found that MyD88 aa155-171 motif not only regulate the activity of transcription factor NF-?B, but also control the production of cytokines and expression of costimulatory molecules. Indeed, aa155-171 motif deleted type MyD88 (MyD88155-171) transfected RAW264.7 cells exhibited the reduced NF-?B and AP-1 activity and interrupted the expression of CD86 and B7H1. Meanwhile, lower level expression of cytokines such as IL-12,IFN-? were also observed by means of cytokine array in MyD88-/-DC trasfected with MyD88155-171 as compared to the MyD88 transfected cells. Thus, aa155-171 motif inside MyD88 could affect the expression of costimulatory molecules, production of cytokines and transduction of Toll like receptor signal pathway, suggesting that this motif may play an important role in regulating responses of innate immune system.

Objective: To prepare an adenovirus, Ad-CD, expressing bacterial cytosine deaminase(CD),and use it for tumor suicide gene therapy. Methods: We constructed a recomb ined adenoviral vector carrying CD or LacZ. 293 packaging cell was trans fected by the newly-constructed plasmid and generated the infectious virus. The n the adenovirus was used to infect C26 cell in vitro. Results: The growth of Ad-CD-infected cell was obviously surpressed after admini stration of 5-FC. Conclusion: CD gene carried by adenoviral vec tor is effective for tumor cell suicide gene therapy in vitro.

VPAC2 is a co-receptor of pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) and mediates multiple bio-functions. In order to construct the CHO line expressing VPAC2 stably, pcDNA-VPAC2 was used to transfect CHO cells. The positive clones were selected by G418 and the clone VPAC2-CHO with high sensitivity to PACAP38 was picked out by its ability to promoting the concentration of cAMP. RT-PCR, Western blot and Immunofluorescenece assay were used to identify the express of VPACS. Binding competition with VPAC2 agonist and the bioactivity of mediating the ligand to promote the concentration of cAMP showed that VPAC2 was expressed effectively in VPAC2-CHO. The results of Scatchard analysis revealed that VAPC2-CHO expressed a receptor density of (1.1 +/- 0.2) pmol/mg protein, respectively, with Kd values of (0.55 +/- 0.10) nmol/L for PACAP38 used as a tracer. The construction of CHO cells expressing VPAC2 specially and functionally lays a foundation not only for the further research on the characters and functions of VPAC2 but also for the screening and characterization of novel agonists of antagonists for VPAC2.
Animals ; Binding, Competitive ; CHO Cells ; Cell Membrane ; drug effects ; metabolism ; Cricetinae ; Cricetulus ; Cyclic AMP ; metabolism ; Gene Expression ; Genetic Vectors ; genetics ; Iodine Radioisotopes ; chemistry ; Pituitary Adenylate Cyclase-Activating Polypeptide ; chemistry ; metabolism ; pharmacology ; Receptors, Vasoactive Intestinal Peptide, Type II ; agonists ; antagonists & inhibitors ; genetics ; metabolism ; Reverse Transcriptase Polymerase Chain Reaction ; Transfection

To observe in vitro the effect of rat drug serum on the proliferation of HSC-T6 hepatic stellate cells in the pharmacokinetic model for determining peoniflorin in Fufang Biejia Ruangan tablet, in order to discover the rational daily administration frequency of Fufang Biejia Ruangan tablet. Fufang Biejia Ruangan tablet was orally administered to rats with different daily administration frequency. Their blood was collected from veins behind eye sockets at different time points before the administration and after the first administration, in order to determine the concentration of peoniflorin in blood plasma and the effect of rat drug serums on the proliferation of HSC-T6. A comprehensive analysis was made on the relationship between pharmacodynamics and pharmacokinetics to determine the rational daily administration frequency of Fufang Biejia Ruangan tablet. The results showed a good correlation between the inhibitory effect of Fufang Biejia Ruangan tablet-contained serum on HSC-T6 and the concentration of peoniflorin in blood. The two-time administration group showed higher pharmacologic and pharmacokinetic AUCs than one-time administration and three-time administration groups. In conclusion, Fufang Biejia Ruangan table is recommended to be taken twice a day for treating liver fibrosis in chronic hepatitis.
Administration, Oral ; Animals ; Area Under Curve ; Benzoates ; administration & dosage ; blood ; pharmacokinetics ; Bridged-Ring Compounds ; administration & dosage ; blood ; pharmacokinetics ; Cell Proliferation ; drug effects ; Cells, Cultured ; Drugs, Chinese Herbal ; administration & dosage ; pharmacokinetics ; Glucosides ; administration & dosage ; blood ; pharmacokinetics ; Hepatic Stellate Cells ; drug effects ; metabolism ; Liver Cirrhosis ; drug therapy ; metabolism ; Male ; Monoterpenes ; Rats ; Rats, Sprague-Dawley ; Tablets ; administration & dosage ; pharmacokinetics

OBJECTIVETo explore the role of the amino acids between 551 and 565 in the cytoplasmic domain of glycoprotein (GP) I b alpha in the VWF binding to GP I b alpha.

METHODSThe VWF binding to GP I b alpha induced by ristocetin was analyzed by flow cytometry, in three GP I b-IX-expressing Chinese hamster ovary (CHO) cell lines 1b9, delta 565 and delta 551, adhesion of above cells on VWF by flow chamber analysis at shear rate of 200 s(-1). The spread of GP I b-IX-expressing cells were stimulated with botrocetin on VWF-coated coverslips by confocal microscope.

RESULTSThe VWF binding to GP I b alpha was higher in delta 565 cells stimulated by ristocetin than in delta 551 or 1b9 cells. The number of delta 565 cells adhered on the VWF-coated-chamber was more than that of controls at shear rate of 200 s(-1). Moreover, the surface spreading areas of delta 565 cells were greater than that of the controls on VWF-coated coverslips.

CONCLUSIONSThe amino acids between 551 and 565 in the cytoplasmic domain of GP I b alpha regulates the VWF binding to GP I b alpha.

Amino Acid Sequence ; Animals ; CHO Cells ; Cricetinae ; Cricetulus ; Female ; Platelet Adhesiveness ; Platelet Glycoprotein GPIb-IX Complex ; genetics ; metabolism ; von Willebrand Factor ; metabolism